AmpC Detection Set
Combination disc set for the identification of AmpC producing Enterobacteriaceae

- Definitive identification of AmpC producers
- Detects all AmpC types
- Helps guide appropriate carbapenem usage
- Minimises reporting of false cephalosporin susceptibility
Mast continues to lead the market in the classification, identification and detection of ESBL and AmpC producing pathogens with the development of the AmpC Detection Set.

**What is AmpC?**

AmpC beta-lactamases are bacterial enzymes that hydrolyse 3rd generation extended spectrum cephalosporins and cephemycins engendering resistance to these categories of antibiotic.

(Fig 1) Expression of *ampC*

**Importance of AmpC detection**

Diagnostically, all types of AmpC producers are equally significant and may lead to therapy failure in critically ill patients.

The onslaught of AmpC resistance represents a major challenge for clinicians as it renders 3rd generation cephalosporins increasingly ineffective.

Of particular concern are the limited treatment options for Gram negative resistant bacteria leading to antibiotic selection pressure and consequent risk of the emergence of carbapenem resistance.

Confirmation of AmpC production supports susceptibility information, permitting carbapenems to be reserved for complicated infections. This may allow selection of a targeted narrow spectrum antibiotic rather than those with broad spectrum activity, minimising the risk of selecting for, or promoting the development of resistance.

**When to suspect AmpC**

AmpC can be suspected in *E.coli* and *Klebsiella* spp. when resistance to cephalosporins, including cefoxitin, is detected.

Suspect isolates may generate an unexpected result for ESBL confirmatory tests due to the induction of AmpC activity caused by ESBL inhibitors.

AmpC can be suspected in strains that have an intrinsic chromosomal *ampC* gene, where the initial susceptibility screen may not indicate resistance.
**Benefits of Mast AmpC Detection Set**

- **Detection of ALL mechanisms of AmpC resistance**
  Combining an AmpC inducer with both ESBL and AmpC inhibitors simultaneously promotes AmpC enzyme induction whilst selectively blocking the enzyme active site. In consequence, plasmid and intrinsic de-repressed, inducible or hyperproduced AmpCs can be detected, irrespective of how ampC genes are encoded or expressed (fig.1)

- **98% sensitivity, 100% specificity**
  Reliable phenotypic AmpC detection minimises the risk of erroneously reporting cephalosporin susceptibility, diminishing any potentially serious consequences

- **Easy to interpret**
  A simple calculation based on zone size comparison indicates the presence of an AmpC producer (Fig.2)

- **Flexibility for multiple applications**
  AmpC Detection Set can be used in conjunction with Mast's AmpC and ESBL Detection Set (D68C) to confirm AmpC production, or as a standalone test to screen *E.coli* and *Klebsiella* spp. isolates for plasmid acquired ampC genes

- **Definitive Identification of AmpC producers**
  The resultant increase in sensitivity and specificity afforded by the novel use of an inducer compound permits a definitive identification, diagnostically superior to more presumptive methods

- **Combination discs manufactured in matched pairs**
  To prevent erroneous results arising from variations in content, the UK Health Protection Agency (HPA)* recommend using only corresponding antibiotic and antibiotic/inhibitor combinations which have been jointly manufactured and QC tested
  (*HPA ARMRL, Summer 2005)

- **Available from Stock**
  In common with the current range of Mast ESBL detection discs, the AmpC Detection Set is provided as a stock product with 12 months shelf life

- **Compatible with Mast disc dispenser**
  Permits consistent orientation of paired discs aiding standardisation for routine testing

**Interpretation**

**AmpC Positive**

- Z<sub>A</sub> ≤ Z<sub>B</sub> + Z<sub>C</sub> ≥ 5mm

**AmpC Negative**

- All zones differ by ≤ 3mm

A Cefpodoxime 10ug + AmpC inducer
B Cefpodoxime 10ug + AmpC inducer + ESBL inhibitor
C Cefpodoxime 10ug + AmpC inducer + ESBL inhibitor + AmpC inhibitors  
(Fig 2)
### Ordering Information

<table>
<thead>
<tr>
<th>Order Code</th>
<th>Product</th>
<th>Pack Size</th>
<th>Usage</th>
</tr>
</thead>
<tbody>
<tr>
<td>D69C</td>
<td>AmpC Detection Set</td>
<td>3 x 50 discs</td>
<td>Confirmation of plasmid and chromosomally encoded AmpC</td>
</tr>
<tr>
<td>D70C</td>
<td>Carbapenamase Detection Set</td>
<td>4 x 50 discs</td>
<td>Detection of MBL and KPC enzyme production</td>
</tr>
<tr>
<td>D88C</td>
<td>AmpC &amp; ESBL Detection Set</td>
<td>4 x 50 discs</td>
<td>Confirmation of AmpC and/or ESBL production</td>
</tr>
<tr>
<td>D52C</td>
<td>Extended Spectrum β lactamase Set</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with no chromosomal de-repressed or inducible AmpC</td>
</tr>
<tr>
<td>D67C</td>
<td>Extended Spectrum β lactamase Set</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with no chromosomal de-repressed or inducible AmpC</td>
</tr>
<tr>
<td>D62C</td>
<td>Cefotaxime 30 &amp; Cefotaxime 30/Clavulanic Acid 10</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with no chromosomal de-repressed or inducible AmpC (* use concurrently with D64C)</td>
</tr>
<tr>
<td>D63C</td>
<td>Cefepime 30 &amp; Cefepime 30/Clavulanic Acid 10</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with chromosomal AmpC</td>
</tr>
<tr>
<td>D64C</td>
<td>Ceftazidime 30 &amp; Ceftazidime 30/Clavulanic Acid 10</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with no chromosomal de-repressed or inducible AmpC (*use concurrently with D62C)</td>
</tr>
<tr>
<td>D66C</td>
<td>Cefpodoxime 10 &amp; Cefpodoxime 10/Clavulanic Acid 1</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with no chromosomal de-repressed or inducible AmpC</td>
</tr>
</tbody>
</table>

---

### Additional products from Mast’s ESBL detection range

<table>
<thead>
<tr>
<th>Order Code</th>
<th>Product</th>
<th>Pack Size</th>
<th>Usage</th>
</tr>
</thead>
<tbody>
<tr>
<td>D70C</td>
<td>Carbapenamase Detection Set</td>
<td>4 x 50 discs</td>
<td>Detection of MBL and KPC enzyme production</td>
</tr>
<tr>
<td>D88C</td>
<td>AmpC &amp; ESBL Detection Set</td>
<td>4 x 50 discs</td>
<td>Confirmation of AmpC and/or ESBL production</td>
</tr>
<tr>
<td>D52C</td>
<td>Extended Spectrum β lactamase Set</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with no chromosomal de-repressed or inducible AmpC</td>
</tr>
<tr>
<td>D67C</td>
<td>Extended Spectrum β lactamase Set</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with no chromosomal de-repressed or inducible AmpC</td>
</tr>
<tr>
<td>D62C</td>
<td>Cefotaxime 30 &amp; Cefotaxime 30/Clavulanic Acid 10</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with no chromosomal de-repressed or inducible AmpC (* use concurrently with D64C)</td>
</tr>
<tr>
<td>D63C</td>
<td>Cefepime 30 &amp; Cefepime 30/Clavulanic Acid 10</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with chromosomal AmpC</td>
</tr>
<tr>
<td>D64C</td>
<td>Ceftazidime 30 &amp; Ceftazidime 30/Clavulanic Acid 10</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with no chromosomal de-repressed or inducible AmpC (*use concurrently with D62C)</td>
</tr>
<tr>
<td>D66C</td>
<td>Cefpodoxime 10 &amp; Cefpodoxime 10/Clavulanic Acid 1</td>
<td>6 x 50 discs</td>
<td>Confirmation of ESBL production in isolates with no chromosomal de-repressed or inducible AmpC</td>
</tr>
</tbody>
</table>

---

United Kingdom  
Mast Group Ltd.  
Mast House  
Derby Road, Bootle  
Merseyside L20 1EA  
Tel: + 44 (0) 151 933 7277  
Fax: + 44 (0) 151 944 1332  
e-mail: sales@mastgrp.com

Germany  
Mast Diagnostica GmbH  
Feldstrasse 20  
DE-23858 Reinfeld  
Tel: + 49 (0) 4533 2007 0  
Fax: + 49 (0) 4533 2007 68  
e-mail: mast@mast-diagnostica.de

France  
Mast Diagnostic  
115 Rue Jules Barni  
CS91106  
80011 Amiens CEDEX 1  
Tel: + 33 (0) 322 80 80 67  
Fax: + 33 (0) 322 80 99 22  
e-mail: info@mast-diagnostic.fr

www.mastgrp.com